Molecular Mechanisms and Targeted Treatments in Colorectal Cancer

Colorectal cancer is driven by a complex interplay of genetic, epigenetic and microenvironmental factors. Somatic mutations in key pathways—including Wnt/β-catenin, EGFR and TGF-β—combine with chromosomal instability, microsatellite instability and CpG island methylator phenotype to generate molecularly distinct tumour subtypes. These subtypes differ in prognosis and therapeutic vulnerability. Aberrant activation of MAPK and PI3K–AKT cascades, together with dysregulated cell-cycle control and evasion of apoptosis, underpin tumour initiation and progression. The tumour microenvironment, comprising immune infiltrates and the resident microbiome, further modulates tumour behaviour and response to therapy. Precision oncology approaches now integrate comprehensive genomic and transcriptomic profiling with immune and microbial signatures to stratify patients. Established targeted agents include anti-EGFR antibodies and anti-angiogenic inhibitors, while novel strategies encompass small-molecule inhibitors of BRAF, MEK and PI3K, immune-checkpoint blockade and microbiome-directed adjuncts. Recent advances in biomarker discovery and functional genomics are paving the way for adaptive treatment regimens that exploit tumour dependencies, overcome resistance mechanisms and ultimately improve patient outcomes on a global scale.

Research from Nature Portfolio

Recent studies have delivered large-scale integrative analyses that link somatic variation with clinical outcome. One investigation of over 1,000 primary colorectal cancers combined whole-genome and transcriptome data to reveal previously unrecognised driver genes, delineate early versus late mutational events and classify tumours into five prognostic expression subtypes. These findings refine risk stratification and suggest novel therapeutic targets within Wnt, EGFR and TGF-β pathways. In parallel, a multi-omics atlas of colon cancer analysed tumour and matched normal tissue across genomic, transcriptomic, T cell receptor and microbiome sequencing. This work established an immunologic constant of rejection signature and a microbiome-driven score that jointly predict survival, offering a composite biomarker for personalised immunomodulatory therapies. Mechanistic insights have emerged from functional studies of translational regulators, notably the EIF3H–HAX1 axis. This axis enhances RAF–MEK–ERK signalling through targeted deubiquitination of HAX1, is induced by Wnt signalling and promotes tumour growth and metastasis. Dual inhibition of Wnt and ERK pathways in high-EIF3H tumours demonstrates synergistic suppression of patient-derived xenografts, highlighting a promising combinatorial strategy.

Molecular Mechanisms and Targeted Treatments in Colorectal Cancer publication trend

The graph below shows the total number of articles in molecular mechanisms and targeted treatments in colorectal cancer across all publications each year (not limited to Nature Index journals).

Technical terms

Microsatellite instability (MSI): A hypermutable phenotype caused by defective DNA mismatch repair leading to length variations in short tandem repeat sequences.

Deubiquitinase: An enzyme that removes ubiquitin from target proteins, regulating their stability and activity.

Neoantigen: A novel peptide generated by tumour-specific mutations that can be recognised by the immune system.

Immunoediting: The process by which the immune system shapes tumour evolution through elimination, equilibrium and escape phases.

Angiogenesis: Formation of new blood vessels from existing vasculature, a process co-opted by tumours to secure nutrients and oxygen.

References

1. Prognostic genome and transcriptome signatures in colorectal cancers. Nature (2024).
2. An integrated tumor, immune and microbiome atlas of colon cancer. Nature Medicine (2023).
3. The EIF3H-HAX1 axis increases RAF-MEK-ERK signaling activity to promote colorectal cancer progression. Nature Communications (2024).
4. Comprehensive review of targeted therapy for colorectal cancer. Signal Transduction and Targeted Therapy (2020).
5. Molecular Mechanisms of Colon Cancer Progression and Metastasis: Recent Insights and Advancements. International Journal of Molecular Sciences (2020).